We support ministers in leading the nation’s health and social care to help people live more independent, healthier lives for longer.
The Committee is examining the relationship between leadership in the NHS and performance/productivity as well as patient safety. It will …
Oral Answers to Questions is a regularly scheduled appearance where the Secretary of State and junior minister will answer at the Dispatch Box questions from backbench MPs
Other Commons Chamber appearances can be:Westminster Hall debates are performed in response to backbench MPs or e-petitions asking for a Minister to address a detailed issue
Written Statements are made when a current event is not sufficiently significant to require an Oral Statement, but the House is required to be informed.
Department of Health and Social Care does not have Bills currently before Parliament
A Bill to make provision about health and social care.
This Bill received Royal Assent on 28th April 2022 and was enacted into law.
A Bill to confer power to amend or supplement the law relating to human medicines, veterinary medicines and medical devices; make provision about the enforcement of regulations, and the protection of health and safety, in relation to medical devices; and for connected purposes.
This Bill received Royal Assent on 11th February 2021 and was enacted into law.
A Bill to make provision in connection with coronavirus; and for connected purposes.
This Bill received Royal Assent on 25th March 2020 and was enacted into law.
To make provision regarding the funding of the health service in England in respect of each financial year until the financial year that ends with 31 March 2024.
This Bill received Royal Assent on 16th March 2020 and was enacted into law.
e-Petitions are administered by Parliament and allow members of the public to express support for a particular issue.
If an e-petition reaches 10,000 signatures the Government will issue a written response.
If an e-petition reaches 100,000 signatures the petition becomes eligible for a Parliamentary debate (usually Monday 4.30pm in Westminster Hall).
Prioritise teachers, school and childcare staff for Covid-19 vaccination
Gov Responded - 23 Feb 2021 Debated on - 11 Jan 2021Advice from the JCVI on the priority groups for a Covid-19 vaccine does not include school/childcare workers. This petition calls for these workers, who cannot distance or use PPE, to be kept safe at work by being put on the vaccine priority list when such a list is adopted into government policy.
We want the Government to commit to not rolling out any e-vaccination status/immunity passport to the British public. Such passports could be used to restrict the rights of people who have refused a Covid-19 vaccine, which would be unacceptable.
Prevent any restrictions on those who refuse a Covid-19 vaccination
Gov Responded - 11 Sep 2020 Debated on - 14 Dec 2020I want the Government to prevent any restrictions being placed on those who refuse to have any potential Covid-19 vaccine. This includes restrictions on travel, social events, such as concerts or sports. No restrictions whatsoever.
Commons Select Committees are a formally established cross-party group of backbench MPs tasked with holding a Government department to account.
At any time there will be number of ongoing investigations into the work of the Department, or issues which fall within the oversight of the Department. Witnesses can be summoned from within the Government and outside to assist in these inquiries.
Select Committee findings are reported to the Commons, printed, and published on the Parliament website. The government then usually has 60 days to reply to the committee's recommendations.
No assessment has been made of the adequacy of levels of parental choice and responsibility to decide the medical care their child receives. Those with parental responsibilities are entitled to give consent for medical treatment on behalf of their children. However, they are not entitled to inappropriate treatment for their children, or to refuse treatment which is in the child’s best interests.
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
It remains the Department’s view that any change to the law in this sensitive area is a matter for Parliament to decide, and an issue of conscience for individual parliamentarians rather than one for Government policy. The Department as no such plans to make any formal assessment.
It remains the Department’s view that any change to the law in this sensitive area is a matter for Parliament to decide, and an issue of conscience for individual parliamentarians rather than one for Government policy. The Department as no such plans to make any formal assessment.
Prevention and early intervention are paramount to preventing Sudden Infant Death Syndrome (SIDS), and we want to ensure that every family receives the support and guidance they need during the early days of parenthood.
Health visitors have an important role supporting child health, wellbeing, and parenting confidence. They support families in improving health literacy, managing minor illnesses, and preventing accidents, including promoting safe sleeping for babies. Health visitors can also work with early years services to ensure that safer sleep messages are promoted across early years services. Further information is available at the following link:
The Department is also working alongside NHS England and the National Child Mortality Database (NMCD) to increase the data bank on SIDS, to increase our evidence base, understanding, and inform actions and policy.
The Gillick competence is a guideline used to determine whether children can provide informed consent based on their level of intelligence, knowledge, and competence. In schools, where requests for parental consent haven’t been responded to, vaccinators may ask for the child’s parents’ contact details to seek oral consent over the phone. For young people, and children in secondary school settings who may be offered the measles, mumps and rubella vaccine alongside other school aged vaccinations, after every attempt to gain parental consent has been exhausted, the School Aged Immunisation Service team may make a clinical decision to give the vaccination using the Gillick competence framework. This allows a child to consent to their own treatment where appropriate, and when they are competent to do so.
The Green Book Chapter two, Information for public health professionals on immunisation, provides guidance on seeking consent for vaccination, including the use of the Gillick competence. Obtaining consent to treatment and assessing the adequacy of the use of the Gillick competence in schools is the responsibility of each service provider.
Adverse events of special interest (AESI) are medical events or conditions that have been identified as possible vaccine safety concerns, based mainly on previous experience with other vaccines and immune-mediated events which theoretically may occur, as vaccines stimulate an immune response. AESIs for COVID-19 vaccines were subject to enhanced surveillance by the Medicines and Healthcare products Regulatory Agency (MHRA) and many other regulators from the start of the United Kingdom’s immunisation programme.
Specifically in relation to AESIs, the MHRA has received 22880 UK spontaneous suspected adverse reaction (ADR) reports across all COVID-19 vaccines. Over 157 million doses of COVID-19 vaccines have been given in the UK. It is important to note that Yellow Card reports are not proof of a side effect occurring, and the incidence of a reaction occurring cannot be determined by these reports. The MHRA considers that the benefits of the COVID-19 vaccines continue to outweigh the risks for the majority of people.
The MHRA acknowledges receipt of every Yellow Card report received, and a team of safety experts follow up for additional information as necessary, including consideration of reports with a fatal outcome, based on the completeness, severity, and clinical details provided in the report. Responses to follow-up requests for ADR reports are recorded and stored with the original report on our ADR database. The information is then passed downstream for use in signal detection and the identification of safety concerns.
The data is available for its core purpose of assessment and signal detection, however, the systems were not designed to quantify follow-up metrics requested in this parliamentary question. As such it is not possible to automatically generate metrics on the proportion of follow-up requests sent. The MHRA has provided information on follow up rates under Freedom of Information, within the 20 day statutory timeframes based on manual review of reports, and is committed to publishing high level data on its website.
The Department has not undertaken such an assessment. The North Central London Integrated Care Board has conducted an impact assessment on the proposals as part of its consultation on proposed changes to maternity, neonatal, and children’s surgical services in North Central London, which is due to close on 17 March 2024. This impact assessment is available at the following link:
https://nclhealthandcare.org.uk/wp-content/uploads/2023/12/ALT-TEXT_Maternity-Neonates-IIA-1.pdf
The Department takes all prevention of future death reports seriously, including working with healthcare partners where appropriate to develop our responses. We are conscious of the statutory deadline for these reports, and the Department will provide a formal response in due course.
On 25 May 2023, the Government announced that the New Hospital Programme (NHP) is expected to represent over £20 billion of capital investment for the financial year 2030/31, and that there would be a rolling programme of investment in health infrastructure in the longer term. Future spending beyond this current spending review period will be subject to the usual spending review processes.
The NHP has developed a third version of its Programme Business Case (PBC) which includes costs for the programme’s future spend. This was approved by the Department’s Joint Investment Committee on 19 February 2024. Following this approval, the PBC will go through Government assurance processes in May 2024.
Future spend will be confirmed through the usual processes of future spending reviews, and all funding allocations for specific schemes within the NHP will only be confirmed once the individual Full Business Cases have been reviewed and agreed by ministers.
Departmental officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE), including on access to medicines such as luspatercept (Reblozyl). The Department has had no discussions with Bristol Myers Squibb on this specific topic.
Luspatercept has a licence in the United Kingdom for the treatment of adult patients with transfusion-dependent anaemia due to very low, and low and intermediate-risk myelodysplastic syndrome with ring sideroblasts, who had an unsatisfactory response to, or are ineligible for, erythropoietin-based therapy. The NICE had to terminate its appraisal of luspatercept for treating anaemia caused by myelodysplastic syndromes because the manufacturer did not provide an evidence submission. The NICE will review this decision if the company decides to make a submission.
In October 2022, Health Education England carried out the fifth national census to capture the size and composition of the public health workforce in England. The scope of the 2022 census was expanded to include additional roles beyond specialists, including public health practitioners, advanced practitioners, specialist community public health nurses, including school nurses and health visitors, and public health apprentices. NHS England plans to conduct the next capacity review of the public health workforce in 2025, and will work with the Department to define the scope of the review.
The NHS Long Term Workforce Plan, published on 30 June 2023, sets out the steps the National Health Service and its partners need to take to deliver a health workforce that meets the needs of the population. This includes a commitment to provide 13% more public health specialist training places from 2023/24, and for the NHS to work with the Department to address demand and supply of the public health workforce in future years.
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance on whether new licensed medicines should be routinely funded by the National Health Service, based on an assessment of their costs and benefits.
The NICE published guidance in 2021 and 2023 recommending Enhertu (trastuzumab deruxtecan) for the treatment of NHS patients with HER2-positive breast cancer through the Cancer Drugs Fund, and it is now available to eligible NHS patients in line with the NICE’s recommendations.
The NICE is currently evaluating Enhertu for the treatment of metastatic HER2-low breast cancer, and published final draft guidance on 5 March 2024 that does not recommend it as a clinically and cost-effective use of NHS resources. Stakeholders have until 19 March 2024 to lodge an appeal against the NICE’s recommendations. The NICE currently expects to publish final guidance on 3 April 2024.
The increase in reported error in 2020/21 was due to the NHS Business Services Authority commencing the reporting of errors identified as part of their NHS Provider Assurance activity.
The NHS Breast Screening Programmes were affected by the COVID-19 pandemic, and some breast screening offices took the decision to pause services temporarily to support the pandemic response. All breast cancer screening services have now recovered from the pandemic, and have no backlog of people waiting to be screened.
Increasing uptake and reducing health inequalities remains paramount as part of the ambitions set out in the NHS Long Term Plan to directly support early detection and diagnosis of breast cancer. Regional commissioners are working closely with cancer alliances and cancer charities to develop uptake plans which address their specific populations needs.
Montelukast remains a safe and effective medicine in the treatment of asthma. Montelukast is indicated for use in the United Kingdom as an add on treatment for asthma patients who are inadequately controlled on inhaled corticosteroid treatment, and can be prescribed for the symptomatic relief of seasonal allergic rhinitis in patients with asthma. There is no licensed indication in the UK for the treatment of allergic rhinitis alone.
Neuropsychiatric effects such as depression have been included in the UK product information for montelukast since 2007. This has been subsequently updated with additional terms based on emerging evidence. This includes the most recent update in 2019, which more fully described the neuropsychiatric effects. In order to remind prescribers of the risk of neuropsychiatric effects with montelukast, a Drug Safety Update article was published by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2019, to accompany the updated warnings.
Following a growing number of Yellow Card reports and queries from patients and caregivers, raising concerns about a potential ongoing lack of awareness of the risk of the neuropsychiatric effects with montelukast, the MHRA is conducting a further review of the current data.
As part of our review, we are evaluating all available evidence, including Yellow Card reports and queries received by the MHRA, literature publications, international regulatory changes, including those made by the United States’ Food and Drug Administration, and are listening to and learning from patients’ experiences. The MHRA has sought advice from our independent expert groups including paediatricians, specialists in mental and respiratory health, as well as experts in medicines safety.
We are considering all relevant regulatory actions that would provide the most effective way of increasing awareness to healthcare professionals, patients, and their caregivers. The MHRA is finalising the review process and will communicate on any further measures to minimise the risk, upon completion of our review.
Montelukast remains a safe and effective medicine in the treatment of asthma. Montelukast is indicated for use in the United Kingdom as an add on treatment for asthma patients who are inadequately controlled on inhaled corticosteroid treatment, and can be prescribed for the symptomatic relief of seasonal allergic rhinitis in patients with asthma. There is no licensed indication in the UK for the treatment of allergic rhinitis alone.
Neuropsychiatric effects such as depression have been included in the UK product information for montelukast since 2007. This has been subsequently updated with additional terms based on emerging evidence. This includes the most recent update in 2019, which more fully described the neuropsychiatric effects. In order to remind prescribers of the risk of neuropsychiatric effects with montelukast, a Drug Safety Update article was published by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2019, to accompany the updated warnings.
Following a growing number of Yellow Card reports and queries from patients and caregivers, raising concerns about a potential ongoing lack of awareness of the risk of the neuropsychiatric effects with montelukast, the MHRA is conducting a further review of the current data.
As part of our review, we are evaluating all available evidence, including Yellow Card reports and queries received by the MHRA, literature publications, international regulatory changes, including those made by the United States’ Food and Drug Administration, and are listening to and learning from patients’ experiences. The MHRA has sought advice from our independent expert groups including paediatricians, specialists in mental and respiratory health, as well as experts in medicines safety.
We are considering all relevant regulatory actions that would provide the most effective way of increasing awareness to healthcare professionals, patients, and their caregivers. The MHRA is finalising the review process and will communicate on any further measures to minimise the risk, upon completion of our review.
Montelukast remains a safe and effective medicine in the treatment of asthma. Montelukast is indicated for use in the United Kingdom as an add on treatment for asthma patients who are inadequately controlled on inhaled corticosteroid treatment, and can be prescribed for the symptomatic relief of seasonal allergic rhinitis in patients with asthma. There is no licensed indication in the UK for the treatment of allergic rhinitis alone.
Neuropsychiatric effects such as depression have been included in the UK product information for montelukast since 2007. This has been subsequently updated with additional terms based on emerging evidence. This includes the most recent update in 2019, which more fully described the neuropsychiatric effects. In order to remind prescribers of the risk of neuropsychiatric effects with montelukast, a Drug Safety Update article was published by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2019, to accompany the updated warnings.
Following a growing number of Yellow Card reports and queries from patients and caregivers, raising concerns about a potential ongoing lack of awareness of the risk of the neuropsychiatric effects with montelukast, the MHRA is conducting a further review of the current data.
As part of our review, we are evaluating all available evidence, including Yellow Card reports and queries received by the MHRA, literature publications, international regulatory changes, including those made by the United States’ Food and Drug Administration, and are listening to and learning from patients’ experiences. The MHRA has sought advice from our independent expert groups including paediatricians, specialists in mental and respiratory health, as well as experts in medicines safety.
We are considering all relevant regulatory actions that would provide the most effective way of increasing awareness to healthcare professionals, patients, and their caregivers. The MHRA is finalising the review process and will communicate on any further measures to minimise the risk, upon completion of our review.
There are approximately 14,000 licensed medicines, and the overwhelming majority are in good supply. However, the medicine supply chain is highly regulated, complex, and global, and supply disruption is an issue which affects countries all around the world.
There are a number of reasons why supply can be disrupted, including manufacturing difficulties, regulatory non-compliance, access to raw materials, sudden demand spikes, or distribution issues. Supply issues are driven by a range of factors, many of which are non-specific to the United Kingdom.
Whilst we can’t always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise, and help mitigate risks to patients. We work closely with industry, the National Health Service, and others, to develop bespoke mitigation plans, which are tailored to each issue, to help ensure patients continue to have access to the medicines they need.
The Spring Budget 2024 announced that the Government is protecting the day-to-day funding of the National Health Service in England, providing an extra £2.45 billion in 2024/25. This will allow the NHS to continue to focus on reducing waiting times, and will bring the NHS’s resource budget in 2024/25 to £164.9 billion. This means that NHS funding will increase from 2023/24, and equates to a real terms increase of 13% since 2019/20.
An additional £3.4 billion of capital funding announced at the budget will aid the NHS’ technological and digital transformation over three years, between 2025/26 and 2027/28. This will provide wider benefits to quality of care and patient outcomes, such as better prevention, and patients living longer and healthier lives, as a result of receiving scans earlier. Devolved administrations, including Scotland, will benefit from additional funding through the Barnett formula.
NHS England commissioned an evaluation to assess the impact of the capsule sponge test in secondary care, for patients on a routine reflux pathway. The evaluation report was completed in September 2023 and the national pilot will conclude in March 2024.
On 26 February 2024, NHS England published the results of the capsule sponge test pilot for secondary care routine reflux and Barrett’s surveillance cohort, which began in January 2021, and launched at 30 hospitals across England. The pilot tested over 8,500 patients with the capsule sponge test. Evaluation of a cohort of patients showed almost eight out of 10 patients, who completed a test, were discharged without the need for further testing, freeing up endoscopy capacity for higher risk patients and those referred for urgent tests for oesophageal cancer. Patients with positive results from the capsule sponge test who were referred on for an endoscopy had the highest prevalence of Barrett’s oesophagus, at 27.2%, compared to zero patients with negative results who completed an endoscopy.
NHS England has not committed to national uptake of capsule sponge, but will continue to support integrated care boards (ICBs) and local systems to deliver in their area. The evaluation report was published and shared with local National Health Service systems including Cancer Alliances, NHS providers, and ICBs to support with local service provision. The evaluation findings should be interpreted and used locally, based on need.
NHS England is continuing to explore other capsule sponge use cases, including in primary and community care settings jointly funded by the National Institute for Health and Care Research and Cancer Research UK. Separately to this, the CYTOPRIME2 project is funded through the NHS Cancer Programme’s Innovation Open Call and is assessing the feasibility and safety of using capsule sponge in a primary care setting, and evaluating key outcome metrics.
We are taking strong action to support children and their families in achieving and maintaining a healthier weight. The Government is investing approximately £300 million to improve support for families though the joint Department of Health and Social Care and Department for Education Family Hubs and Start for Life Programme. The programme will implement many elements of the Best Start for Life Vision and is delivering a step change in outcomes for babies, children, and their parents and carers in 75 local authorities in England, including those with high levels of deprivation.
The funding package includes £50 million to invest in infant feeding services, which will enable participating local authorities to design and deliver a blended offer of advice and support, in line with local needs.
We support more than three million children through the Healthy Foods Scheme. We also support parents with primary aged children in England to eat well, and move more, through Better Health Families. This includes healthy eating advice and easy recipes, a Food Scanner app to help families to swap less healthy foods and drinks to healthier alternatives, and the Healthy Steps email-programme to inspire and support parents to take easy steps to improve their families' health and wellbeing.
We work with the Department for Education to ensure that children are provided healthy food options in early years settings, and in school. For children aged zero to five years old, the Early Years Foundation Stage framework states that where children are provided with meals, snacks, and drinks, they must be healthy, balanced, and nutritious. The Eat Better, Start Better guidelines and example menus support parents, carers, and anyone working with children to provide healthy food options.
The School Food Standards are set in legislation and require that school caterers serve healthy and nutritious food and drinks, to ensure children get the energy and nutrition they need throughout the school day. Foods high in fat, salt, and sugar are restricted. We are also helping schools boost physical activity to help children maintain a healthy weight and good overall health through the Primary School PE and Sport Premium and the School Games Organiser Network.
In addition, primary school children are educated about healthy eating through the relationships, sex, and health education curriculum. By the end of primary school, pupils should know what constitutes a healthy diet, the principles of planning and preparing a range of healthy meals, the characteristics of a poor diet, and risks associated with unhealthy eating. We have programmes to identify children living with excess weight, and local authorities and the National Health Service in England provide weight management services.
The National Child Measurement Programme monitors the weight status of children at the start and end of primary school. The programme provides is a useful prompt to parents and schools to support healthy eating and physical activity. Data is used to help local authorities plan healthy weight, food and activity support and services for children and their families.
Local authorities can fund weight management services to support children and families, to achieve a healthier weight from their Public Health Grant. The NHS has commissioned a number of Complications from Excess Weight clinics across England for children and young people living with complications related to severe obesity. We are also delivering an ambitious programme of work to create a healthier environment to help people achieve and maintain a healthier weight.
Regulations on out of home calorie labelling for food sold in large businesses, including restaurants, cafes, and takeaways, came into force in April 2022. Restrictions on the placement of products high in fat, sugar, or salt in key selling locations, came into force on 1 October 2022. We will be implementing restrictions on the sale of less healthy products by volume price, for instance three for two offers, and will introduce restrictions on the advertising of less healthy products before 9:00pm on television. We will also be implementing restrictions on paid for online advertising for less healthy products, from 1 October 2025.
We are working with the food industry to ensure it is easier for the public to make healthier choices and make further progress on reformulation. In addition, the Food Data Transparency Partnership will help enable and encourage food companies to voluntarily demonstrate progress on the healthiness of their sales.
We are taking strong action to support children and their families in achieving and maintaining a healthier weight. The Government is investing approximately £300 million to improve support for families though the joint Department of Health and Social Care and Department for Education Family Hubs and Start for Life Programme. The programme will implement many elements of the Best Start for Life Vision and is delivering a step change in outcomes for babies, children, and their parents and carers in 75 local authorities in England, including those with high levels of deprivation.
The funding package includes £50 million to invest in infant feeding services, which will enable participating local authorities to design and deliver a blended offer of advice and support, in line with local needs.
We support more than three million children through the Healthy Foods Scheme. We also support parents with primary aged children in England to eat well, and move more, through Better Health Families. This includes healthy eating advice and easy recipes, a Food Scanner app to help families to swap less healthy foods and drinks to healthier alternatives, and the Healthy Steps email-programme to inspire and support parents to take easy steps to improve their families' health and wellbeing.
We work with the Department for Education to ensure that children are provided healthy food options in early years settings, and in school. For children aged zero to five years old, the Early Years Foundation Stage framework states that where children are provided with meals, snacks, and drinks, they must be healthy, balanced, and nutritious. The Eat Better, Start Better guidelines and example menus support parents, carers, and anyone working with children to provide healthy food options.
The School Food Standards are set in legislation and require that school caterers serve healthy and nutritious food and drinks, to ensure children get the energy and nutrition they need throughout the school day. Foods high in fat, salt, and sugar are restricted. We are also helping schools boost physical activity to help children maintain a healthy weight and good overall health through the Primary School PE and Sport Premium and the School Games Organiser Network.
In addition, primary school children are educated about healthy eating through the relationships, sex, and health education curriculum. By the end of primary school, pupils should know what constitutes a healthy diet, the principles of planning and preparing a range of healthy meals, the characteristics of a poor diet, and risks associated with unhealthy eating. We have programmes to identify children living with excess weight, and local authorities and the National Health Service in England provide weight management services.
The National Child Measurement Programme monitors the weight status of children at the start and end of primary school. The programme provides is a useful prompt to parents and schools to support healthy eating and physical activity. Data is used to help local authorities plan healthy weight, food and activity support and services for children and their families.
Local authorities can fund weight management services to support children and families, to achieve a healthier weight from their Public Health Grant. The NHS has commissioned a number of Complications from Excess Weight clinics across England for children and young people living with complications related to severe obesity. We are also delivering an ambitious programme of work to create a healthier environment to help people achieve and maintain a healthier weight.
Regulations on out of home calorie labelling for food sold in large businesses, including restaurants, cafes, and takeaways, came into force in April 2022. Restrictions on the placement of products high in fat, sugar, or salt in key selling locations, came into force on 1 October 2022. We will be implementing restrictions on the sale of less healthy products by volume price, for instance three for two offers, and will introduce restrictions on the advertising of less healthy products before 9:00pm on television. We will also be implementing restrictions on paid for online advertising for less healthy products, from 1 October 2025.
We are working with the food industry to ensure it is easier for the public to make healthier choices and make further progress on reformulation. In addition, the Food Data Transparency Partnership will help enable and encourage food companies to voluntarily demonstrate progress on the healthiness of their sales.
Smoking is the number one entirely preventable cause of ill-health, disability, and death in this country. It is responsible for 80,000 deaths in the United Kingdom a year, and one in four of all UK cancer deaths. It costs our country £17 billion a year, £14 billion of which is through lost productivity alone. It puts huge pressure on the National Health Service and social care, costing over £3 billion a year. This is why the Government is committed to creating the first smokefree generation, ensuring no child born after 1 January 2009 will ever legally be sold tobacco.
The tenth Conference of Parties (COP10) to the World Health Organisation Framework Convention on Tobacco control was an opportunity for the UK to showcase our international leadership on tobacco control. No decisions from COP10 will impact our plans to create the first smokefree generation, or our policies on vaping. I will update the House shortly on the outcomes from COP10.
There are no plans to make such an assessment. As set out in the National Partnership Agreement for Health and Social Care for England, healthcare services in all prisons in England, including HMP Wandsworth, are commissioned by NHS England to national specifications, to make sure that prisoners receive the same standards of healthcare as the general population.
The Government commissioned the Patient Safety Commissioner (PSC) to produce a report on redress for those affected by sodium valproate and pelvic mesh. We are grateful to the PSC and her team for completing this report, and our sympathies remain with those affected by sodium valproate and pelvic mesh. The Government is now carefully considering the PSC’s recommendations, and will respond substantively in due course.
The Department recognises the valued contribution that mental health and suicide prevention voluntary, community and social enterprise organisations make in supporting people with their mental health.
During the pandemic, we provided £10.2 million of additional funding to support mental health charities, including Samaritans and the Campaign Against Living Miserably, and over £34 million to organisations supporting people who experience loneliness.
More recently, we announced that 79 organisations across the country have been allocated funding through the £10 million suicide prevention grant fund. These organisations, from local, community-led organisations through to national, are delivering a broad and diverse range of activity that will prevent suicides and save lives.
We have also announced that £8 million is being made available for 24 early support hubs across the country, a number of which will be run by voluntary, community and social enterprise organisations.
The current policy is to offer the shingles vaccine to anyone who turned 65 and 70 years old after 1 September 2023, as well as to anyone aged 50 years and older who is at higher risk of serious complications. This policy has significantly improved the already very successful programme.
People aged 66 to 69 years old on 1 September 2023, who do not have a severely weakened immune system, will become eligible for shingles vaccination when they turn 70 years old. Those with a severely weakened immune system are eligible for the shingrix vaccine from 50 years old, due to their increased risk. Anyone who is unsure if they are at higher risk of complications from shingles should speak to their general practitioner. It is important that anyone eligible takes up this offer to protect themselves.
The Government’s policy on groups eligible for the shingles vaccination programme is based on recommendations by the independent expert body, the Joint Committee on Vaccination and Immunisation and the scope and speed of any expansion of a programme is decided between the UK Health Security Agency, the Department, and NHS England.
The UK Health Security Agency (UKHSA) works closely with charities such as Jo’s Cervical Cancer Trust and the Teenage Cancer Trust to develop resources to raise awareness and educate young girls and boys about the human papillomavirus (HPV) vaccine and related cancers. The UKHSA has helped develop education resources for schools called EDUCATE, co-developed with teenagers and the Health Protection Research Unit on Behavioural Science and Evaluation.
School Aged Immunisation Service (SAIS) providers have continuously been focusing on HPV programme recovery since the pandemic and the school closures, and have robust catch-up plans in place for HPV vaccination based on population need, and utilising opportunities from the HPV programme change in September 2023 to deliver further catchup activities from the academic year 2023/24 using innovative models.
The UKHSA monitors uptake for immunisation programmes for teenagers. Annual published statistics help local NHS Screening and Immunisation teams develop plans to improve uptake and reduce inequalities in collaboration with key partners, including Directors of Public Health, and teams in local authorities.
The Shingrix programme was recommended by the Joint Committee on Vaccination and Immunisation (JCVI), to provide better and longer lasting population-level protection from a younger age than the previous Zostavax programme. The Shingrix shingles vaccination programme was introduced from September 2023, to offer two doses of the vaccine to immunocompetent individuals turning 65 and 70 years old, and severely immunosuppressed adults over 50 years old.
A cost-effectiveness review by the JCVI concluded that although the highest monetary benefit would be to provide the Shingrix vaccination at 65 years old, by offering it at 60 years old the highest number of cases would be prevented. For immunosuppressed individuals, Shingrix was determined to be cost-effective between the ages of 50 to 90 years old.
To avoid undue additional pressure on National Health Service delivery services, the Shingrix vaccine will be delivered in a phased approach over 10 years, after which the vaccine would then be offered routinely from 60 years old.
The Government does not currently routinely record the total number of people with long COVID, or new cases identified. However, the most recent data from the Office of National Statistics (ONS) shows that for the four week period ending 5 March 2023: 1.9 million people, or 2.9% of the population, in private households in the United Kingdom reported experiencing long COVID symptoms; 83,000 people first had, or suspected they had, COVID-19 less than 12 weeks previously; 1.73 million people had symptoms for 12 or more weeks, 1.3 million people for at least a year and 762,000 for at least two years; and 1.5 million people reported day-to-day activities adversely affected. Of these, 381,000 people reported that their ability to undertake day-to-day activities had been limited a lot.
On 25 April 2024, the ONS will be publishing additional analysis from the fortnightly Winter Coronavirus (COVID-19) Infection Study, including data on trends in ongoing symptoms of COVID-19. This article will expand on the existing analysis published in the Winter Coronavirus (COVID-19) Infection Study’s data tables, to look more in depth at trends in self-reported symptoms of COVID-19, including ongoing symptoms and associated risk factors.
More and more people are getting support with their mental health thanks to investments made through the NHS Long Term Plan. Unfortunately, demand has risen as the impacts of the COVID-19 pandemic and the rise in the cost of living on people’s mental health continues to be felt. This means that some people are facing waiting times that are much longer than we would like.
We are providing record levels of investment and increasing the mental health workforce to expand and transform National Health Service mental health services, to expand access and reduce waiting times. Between 2018/19 and 2023/24, NHS spending on mental health has increased by £4.6 billion in cash terms, as compared to the target of £3.4 billion in cash terms set out at the time of the Long Term Plan. The NHS Long Term Plan committed to grow the mental health workforce by an additional 27,000 staff between 2019/20 and 2023/24. We are making positive progress, delivering two-thirds of this, or 17,000 additional staff, by September 2023, with further significant growth expected by the end of this financial year.
The NHS is also working towards implementing five new waiting time measures for people requiring mental healthcare in both accident and emergency and in the community, for both adults, and children and young people. This includes working towards improving the quality of data that we have on waiting times for people requiring mental healthcare, in both accident and emergency and in the community. NHS England began publishing this new data in 2023 to improve transparency and drive local accountability.
The Government recognises the significant impact that youth health can have across a person’s life course, and is committed to keeping young people healthy, preventing ill-health, and providing treatment and support where needed. The Department leads a range of universal public health interventions and guidance for those aged between zero and 19 years old, that provide universal support, and help identify further needs and safeguarding concerns for children and young people most at-risk.
People with both physical and mental health conditions face poorer clinical outcomes, and a significantly lower quality of life, than people with a physical health condition alone. This is why the Government is rolling out mental health support teams to schools and colleges in England, to detect and offer evidence-based interventions to young people experiencing mild-to-moderate mental health issues. These currently cover 3.4 million children, or approximately 35% of pupils, which will increase to 50% by 2025. When deciding where to introduce mental health support teams, integrated care boards consider how teams will reach young people most at risk of poor outcomes. In addition, on 27 February 2024 we announced extra funding for 24 early support hubs for young people across England, so that thousands of children and young people will receive earlier, open-access mental health interventions in local communities.
We are taking strong action to support children and their families in achieving and maintaining a healthier weight. The Government is investing approximately £300 million to improve support for families though the joint Department of Health and Social Care and Department for Education Family Hubs and Start for Life Programme. The programme will implement many elements of the Best Start for Life Vision and is delivering a step change in outcomes for babies, children, and their parents and carers in 75 local authorities in England, including those with high levels of deprivation.
The funding package includes £50 million to invest in infant feeding services, which will enable participating local authorities to design and deliver a blended offer of advice and support, in line with local needs.
We support more than three million children through the Healthy Foods Scheme. We also support parents with primary aged children in England to eat well, and move more, through Better Health Families. This includes healthy eating advice and easy recipes, a Food Scanner app to help families to swap less healthy foods and drinks to healthier alternatives, and the Healthy Steps email-programme to inspire and support parents to take easy steps to improve their families' health and wellbeing.
We work with the Department for Education to ensure that children are provided healthy food options in early years settings, and in school. For children aged zero to five years old, the Early Years Foundation Stage framework states that where children are provided with meals, snacks, and drinks, they must be healthy, balanced, and nutritious. The Eat Better, Start Better guidelines and example menus support parents, carers, and anyone working with children to provide healthy food options.
The School Food Standards are set in legislation and require that school caterers serve healthy and nutritious food and drinks, to ensure children get the energy and nutrition they need throughout the school day. Foods high in fat, salt, and sugar are restricted. We are also helping schools boost physical activity to help children maintain a healthy weight and good overall health through the Primary School PE and Sport Premium and the School Games Organiser Network.
In addition, primary school children are educated about healthy eating through the relationships, sex, and health education curriculum. By the end of primary school, pupils should know what constitutes a healthy diet, the principles of planning and preparing a range of healthy meals, the characteristics of a poor diet, and risks associated with unhealthy eating. We have programmes to identify children living with excess weight, and local authorities and the National Health Service in England provide weight management services.
The National Child Measurement Programme monitors the weight status of children at the start and end of primary school. The programme provides is a useful prompt to parents and schools to support healthy eating and physical activity. Data is used to help local authorities plan healthy weight, food and activity support and services for children and their families.
Local authorities can fund weight management services to support children and families, to achieve a healthier weight from their Public Health Grant. The NHS has commissioned a number of Complications from Excess Weight clinics across England for children and young people living with complications related to severe obesity. We are also delivering an ambitious programme of work to create a healthier environment to help people achieve and maintain a healthier weight.
Regulations on out of home calorie labelling for food sold in large businesses, including restaurants, cafes, and takeaways, came into force in April 2022. Restrictions on the placement of products high in fat, sugar, or salt in key selling locations, came into force on 1 October 2022. We will be implementing restrictions on the sale of less healthy products by volume price, for instance three for two offers, and will introduce restrictions on the advertising of less healthy products before 9:00pm on television. We will also be implementing restrictions on paid for online advertising for less healthy products, from 1 October 2025.
We are working with the food industry to ensure it is easier for the public to make healthier choices and make further progress on reformulation. In addition, the Food Data Transparency Partnership will help enable and encourage food companies to voluntarily demonstrate progress on the healthiness of their sales.
In the last 12 months to December 2023, 41% of the 407,000 appointments in Bristol East were delivered on the same day they were booked, and 84.1% were delivered within two weeks of booking. NHS England publishes monthly data on General Practice Appointments, including the approximate length of time between appointments being booked and taking place, but this is not a proxy for waiting times. There are a number of factors which can influence the timing of appointments, and it is not possible to estimate the time between the patient’s first attempt to contact their surgery, and an appointment.
Every baby is allocated a National Health Service number as soon as their birth is notified by the attending midwife. This is linked to the NHS number of the birth mother. Once registered at a general practice (GP) surgery, a baby will also have a GP record. This is the first digital health record which most babies will receive, and is linked to their existing NHS number.
The aim of the Digital Personal Child Health Record programme is not to create a new, standalone record, but to use existing infrastructure to facilitate better coordination between existing records. This will support families in accessing the information they need when they need it, and for professionals to offer more informed, joined-up care.
We have improved access to relevant content and information about maternity, early years, and Start for Life, via the NHS App, and made it easier for families to register a new baby digitally at a GP practice. Over 2000 practices have already adopted the solution, which consists of an online registration service and a new paper form. GPs will be contractually required to adopt and offer both formats, from October 2024.
We have also prepared the launch of a pilot programme which will allow anyone with parental responsibility to apply digitally for access to their child’s record, for any child up to 13 years old. This has now launched in 70 GPs in England, and will make it much easier for parents to manage a child's digital health record. For example, once rolled out across England, this will enable the parent or carer to view their baby’s digital GP record, book appointments, and request prescriptions, all via the NHS App.
Every baby is allocated a National Health Service number as soon as their birth is notified by the attending midwife. This is linked to the NHS number of the birth mother. Once registered at a general practice (GP) surgery, a baby will also have a GP record. This is the first digital health record which most babies will receive, and is linked to their existing NHS number.
The aim of the Digital Personal Child Health Record programme is not to create a new, standalone record, but to use existing infrastructure to facilitate better coordination between existing records. This will support families in accessing the information they need when they need it, and for professionals to offer more informed, joined-up care.
We have improved access to relevant content and information about maternity, early years, and Start for Life, via the NHS App, and made it easier for families to register a new baby digitally at a GP practice. Over 2000 practices have already adopted the solution, which consists of an online registration service and a new paper form. GPs will be contractually required to adopt and offer both formats, from October 2024.
We have also prepared the launch of a pilot programme which will allow anyone with parental responsibility to apply digitally for access to their child’s record, for any child up to 13 years old. This has now launched in 70 GPs in England, and will make it much easier for parents to manage a child's digital health record. For example, once rolled out across England, this will enable the parent or carer to view their baby’s digital GP record, book appointments, and request prescriptions, all via the NHS App.
While the Government’s policy remains that there are no plans to review the list of medical conditions that entitle someone to apply for a medical exemption certificate, there are extensive arrangements currently in place in England to ensure that prescriptions are affordable for everyone.
Around 89% of prescription items are dispensed free of charge in the community in England, and there are a wide range of exemptions from prescription charges already in place, for which those with cystic fibrosis may be eligible. Eligibility depends on the patient’s age, whether they are in qualifying full-time education, whether they are pregnant or have recently given birth, or whether they are in receipt of certain benefits or a war pension.
People on low incomes can apply for help with their health costs through the NHS Low Income Scheme. The scheme provides income related help to people who are not automatically exempt from charges, but who may be entitled to full or partial help if they have a low income and savings below a defined limit.
To support those with greatest need, who do not qualify for an exemption or the NHS Low Income Scheme, prescription prepayment certificates (PPCs) are available. PPCs allow people to claim as many prescriptions as they need, for a set cost.
Data on how many dental nurses, dental hygienists, dental technicians, dental therapists, orthodontic therapists, and clinical dental technicians are registered with the General Dental Council (GDC) is available at the following link:
https://www.gdc-uk.org/about-us/what-we-do/the-registers/registration-reports
In order to practise in the United Kingdom, all members of the dental team must be registered with the GDC. The Department does not hold data on the number of employed dental nurses, dental hygienists, dental technicians, dental therapists, orthodontic dentists, or clinical technicians.
The General Dental Council (GDC) is the independent regulator of dentists and dental care professionals (DCPs) practising in the United Kingdom and enforces the standards they must adhere to. In order to practise in the UK, all dentists and DCPs are required to hold registration with the GDC.
The Department does not hold data on how many dentists have been registered with the GDC. Data on the registration of dentists and DCPs with the GDC is held by the GDC. The GDC regularly publish registration reports on their website at the following link:
https://www.gdc-uk.org/about-us/what-we-do/the-registers/registration-reports
The following table shows the number of dentists with National Health Service activity in England only between the years 2010/11 to 2022/23:
Number of dentists with NHS activity in England
Year | Number of dentists |
2010/11 | 22,799 |
2011/12 | 22,920 |
2012/13 | 23,201 |
2013/14 | 23,723 |
2014/15 | 23,947 |
2015/16 | 24,089 |
2016/17 | 24,007 |
2017/18 | 24,308 |
2018/19 | 24,545 |
2019/20 | 24,684 |
2020/21 | 23,733 |
2021/22 | 24,272 |
2022/23 | 24,151 |
Source: Data is from the NHS Dental Statistics for England Annual Report 2017-18 (Workforce Table 8a) and the NHS Dental Statistics for England Annual Report 2022-23 (Workforce Table 1a). The reports are available at the following link:
https://digital.nhs.uk/data-and-information/publications/statistical/nhs-dental-statistics
Health services in Scotland are the responsibility of the Scottish Government.
Anyone living in Scotland who has been infected or affected by infected blood or blood products has access to specialist psychological support services. There are two such services established by the Scottish Government and managed by NHS Lothian: the Inherited Bleeding Disorders Psychological Support Service, which is available for any patients with a bleeding disorder or their family, and the Scottish Infected Blood Psychological Service. Both services can see patients from across Scotland by means of outreach services, virtually using the NHS Near Me service, or by telephone.
Clinicians utilise the best available evidence, including guidance from The National Institute for Health and Care Excellence (NICE), to determine appropriate treatments to be made available to patients via the National Health Service.
The NICE runs an interventional procedures programme to assess the efficacy and safety of interventional procedures used for treatment or diagnosis, to determine whether they work well enough and are safe enough for use in the NHS. The programme can assess procedures that involve incision, puncture, and entry into a body cavity, or that use ionising, electromagnetic, or acoustic energy.
The NICE’s interventional procedures programme is not currently looking at this procedure in relation to the treatment of eye problems, and there has been no notification to the NICE for consideration of photobiomodulation for treatment of those with severe eye problems.
The Department is committed to partnering with industry, patients, and the wider health and social care system to ensure effective and innovative medical technologies that support the continued delivery of high-quality care and outstanding patient safety, are available to patients. Innovators can sign up to the NHS Innovation Service for guidance on the key steps to introduce their idea or product to the NHS.
The current policy offers the shingles vaccine shingrix to anyone who turned 65 or 70 years old on or after 1 September 2023, and to anyone aged 50 years old and over, who is at higher risk of serious complications as a result of having a severely weakened immune system. This approach has been used in the effective implementation of previous immunisation programmes. Whilst some individuals may have to wait until they are eligible, the population benefit of adopting this approach is greater, and means that many individuals will receive the vaccine sooner and will benefit for longer.
The approach is modelled on the first shingles programme, optimising achievements within the resources and capacity of the National Health Service, while being delivered alongside other important healthcare priorities, and avoiding undue additional pressure on NHS delivery services. An assessment of the potential impact of not providing the vaccine to people aged 66 to 69 years old is not required, as they remain eligible to receive a shingles vaccination when they turn 70 years old, as they would have done prior to 1 September 2023.
No assessment has been made of the impact of legalising assisted suicide on palliative care. The Government recognises that access to high-quality, personalised palliative and end of life care can make a significant difference to individuals and their families, at a sensitive time.
While the National Health Service has always been required to commission appropriate palliative and end of life care services to meet the reasonable needs of their population, as part of the Health and Care Act 2022, palliative care services were added to the list of services an integrated care board must commission, promoting a more consistent national approach and supporting commissioners in prioritising palliative and end of life care.
Abortion statistics for England and Wales for 2021, and from January to June for 2022, have been published on the GOV.UK website, and are available respectively at the following links:
Full 12-month abortion statistics for 2022 are provisionally scheduled to be published in May 2024. The date of the publication of abortion statistics for 2023 will be announced in due course.
The situation remains as set out in April 2023. The implementation of the Liberty Protection Safeguards (LPS) has been delayed beyond the life of this Parliament. We will therefore not be publishing a timetable for the introduction of the LPS at this time.